On this page
What is 5-HTP?
5-Hydroxytryptophan (5-HTP) is an amino acid and the direct biochemical precursor to serotonin (5-hydroxytryptamine, 5-HT). It is the intermediate compound in the two-step pathway from dietary tryptophan to serotonin: tryptophan → 5-HTP (via tryptophan hydroxylase) → serotonin (via aromatic L-amino acid decarboxylase, AADC). Commercially, 5-HTP is extracted from the seeds of Griffonia simplicifolia — a West African shrub whose seeds naturally contain 5–10% 5-HTP by dry weight, the only commercially viable plant source. [5]
Unlike tryptophan (an essential amino acid obtained from diet), 5-HTP is not consumed in meaningful quantities from food — it exists transiently in the biosynthetic pathway and is not present at significant concentrations in any common food. This makes 5-HTP a supplement with no meaningful food-based equivalent and a pharmacologically specific mechanism of action: it raises serotonin, and it does so more reliably and with less competition than tryptophan supplementation. [1]
How 5-HTP works — bypassing two bottlenecks
Bypassing tryptophan hydroxylase (the rate-limiting step): The conversion of tryptophan to 5-HTP by tryptophan hydroxylase (TPH1 in the gut, TPH2 in the brain) is the slowest step in serotonin biosynthesis — it is always operating near its maximum rate and is heavily regulated. Supplementing with 5-HTP bypasses this bottleneck entirely: the body converts 5-HTP to serotonin via AADC rapidly and with high efficiency. [1]
Bypassing blood-brain barrier transport competition: Tryptophan competes with five other large neutral amino acids (LNAAs — leucine, isoleucine, valine, tyrosine, phenylalanine) for the same BBB transporter (LAT1). A high-protein meal floods the blood with competing LNAAs, dramatically reducing tryptophan's CNS entry. 5-HTP uses a different, less competitive transport mechanism — making its CNS delivery substantially more reliable across a range of dietary conditions. [2]
CNS serotonin conversion: Once in the CNS, 5-HTP is decarboxylated by AADC (the same enzyme that converts L-DOPA to dopamine) using pyridoxal phosphate (vitamin B6) as cofactor. The resulting serotonin is stored in vesicles in serotonergic neurons and released into synapses upon neuronal firing. Elevated synaptic serotonin produces the sleep-promoting, mood-stabilising, and appetite-suppressing effects confirmed in the RCT literature. [1]
Clinical evidence
| Study | Design | n | Key finding | Grade |
|---|---|---|---|---|
| Wyatt RJ et al. (1971) — Science doi:10.1126/science.169.3940.17 |
Double-blind crossover, 3 wk | 7 | 5-HTP 200mg/day significantly increased REM sleep latency and NREM slow-wave sleep depth vs placebo. First controlled trial demonstrating 5-HTP's sleep architecture effects. Small but foundational — established the mechanism basis for subsequent sleep trials. | B |
| Cangiano C et al. (1992) — Am J Clin Nutr doi:10.1093/ajcn/56.5.863 |
Double-blind RCT, 6 wk | 20 | 5-HTP 900mg/day vs placebo in obese women. Significant reduction in carbohydrate intake and total caloric intake in 5-HTP group. Self-reported satiety scores significantly higher. Weight loss of 1.5kg vs 0.1kg in placebo. The landmark appetite-reduction trial — widely cited in weight management literature. | A |
| Puttini PS & Caruso I (1992) — J Int Med Res doi:10.1177/030006059202000101 |
Double-blind RCT, 90 days | 50 | 5-HTP 100mg 3×/day vs placebo in fibromyalgia patients. Significant improvements in pain, morning stiffness, sleep quality, fatigue, and anxiety scores. While fibromyalgia is a specific condition, the broad serotonergic improvement across multiple endpoints supports the CNS serotonin mechanism. | A |
| Shaw K et al. (2002) — Cochrane Database Syst Rev doi:10.1002/14651858.CD003198 |
Cochrane systematic review | Pooled | Review of 5-HTP and tryptophan for depression. Found 5-HTP significantly superior to placebo for depressive symptoms across 2 qualifying RCTs. Noted evidence base is "limited by the small number of studies" — concluded promising but insufficiently powered. Quality caveat appropriately noted. | B |
| Bruni O et al. (2004) — Eur J Pediatr Neurol doi:10.1016/j.ejpn.2004.07.009 |
Double-blind RCT, 6 months | 45 | 5-HTP (2mg/kg/day) vs placebo in children with sleep terrors. Significant reduction in sleep terror frequency and severity. The long duration (6 months) and significant results in a paediatric sleep disorder population demonstrate sleep-stage architecture effects beyond simple sleep onset. Not applicable to adult sleep-onset specifically but mechanistically relevant. | A |
The 5-HTP evidence base spans sleep, mood, appetite, and pain — all consistent with elevated central serotonergic tone. The Cangiano 1992 appetite trial remains the most cited for weight management. The Cochrane review (Shaw 2002) gives an honest picture: the depression evidence is real but underpowered — 5-HTP is not an evidence-based treatment for clinical depression but has a role as a mood support supplement for mild low mood in non-medicated individuals. [3]
Dosage and protocol
Evidence-based protocol
Sleep: 100–200mg taken 30–60 minutes before bed. Begin at 50mg for 3–5 days to assess GI tolerance (nausea is the most common dose-limiting side effect). Increase to 100–200mg once tolerated. Mood and appetite: 50–100mg with each main meal (3×/day). The Cangiano trial used 300mg 3×/day — start lower and titrate. Take with food to reduce nausea. [4]
Vitamin B6 co-administration
AADC — the enzyme that converts 5-HTP to serotonin — requires pyridoxal phosphate (the active form of vitamin B6) as a cofactor. B6 deficiency impairs this conversion step. Most Western and Indian diets provide adequate B6, but individuals with low dietary variety, alcoholism, or taking B6-depleting medications (isoniazid, common in India's TB treatment protocols) may benefit from ensuring adequate B6 alongside 5-HTP. A standard multivitamin providing 1.3mg B6 is sufficient — high-dose supplemental B6 is not required. [1]
Duration and cycling
Most RCTs run for 4–12 weeks. Long-term continuous 5-HTP supplementation (>12 weeks) has not been adequately studied. Theoretical concern: chronic exogenous 5-HTP may downregulate tryptophan hydroxylase expression (feedback inhibition), potentially reducing endogenous serotonin synthesis capacity when 5-HTP is discontinued. A conservative approach is to use 5-HTP for defined periods (4–8 weeks for sleep improvement, with breaks) rather than indefinite continuous supplementation. [6]
5-HTP vs L-tryptophan vs melatonin
India-specific context
Growing sleep and mood supplement category — good quality control, SSRI interaction underreported
India's rapidly rising SSRI prescription volume (driven by growing mental health awareness and psychiatry access) creates a specific risk: consumers with depression or anxiety who are already on SSRIs may independently purchase 5-HTP for sleep or mood support without realising the contraindication. Indian e-commerce platforms do not routinely display drug interaction warnings at the point of sale. If you are currently prescribed any antidepressant, always inform your treating physician before adding any serotonergic supplement. [5]
Lab test data
Brand comparison
| Brand & product | ₹/month | Dose / form | Interaction warning? | Our take |
|---|---|---|---|---|
| NOW Foods 5-HTP 100mg (imported via iHerb) | ₹700–₹1,000 | 100mg Griffonia extract, ≥98% 5-HTP | Yes — SSRI warning on label | The international benchmark for 5-HTP quality. SSRI contraindication explicitly stated. COA available. GMP certified. Top India pick for transparency and quality. |
| Natrol 5-HTP 100mg (imported) | ₹800–₹1,200 | 100mg, time-release formulation | Yes — drug interaction section | Time-release formulation extends absorption over 4–6 hours — potentially better for mood and appetite applications (sustained level vs peak-and-trough). Good label transparency. |
| Healthkart / MuscleBlaze 5-HTP (domestic) | ₹500–₹800 | 100mg — no Griffonia purity stated | No SSRI warning | Domestic Indian brands with accessible pricing but incomplete labelling. No SSRI interaction warning is a safety concern for a compound with this specific contraindication. Acceptable quality but not recommended without improved safety communication. |
| Generic marketplace 5-HTP capsules | ₹300–₹600 | Purity and source unstated | No warnings provided | Without purity specification and SSRI warnings, these products create real safety risk. The compound is pharmacologically potent enough that both quality and interaction warnings matter. Avoid in favour of products with COA and explicit contraindication labelling. |
Related conditions
Sleep onset difficulty and sleep quality
Best-evidenced application for non-medicated individuals. 5-HTP increases serotonin availability which is converted to melatonin in the pineal gland — improving both sleep onset latency and sleep architecture (increased slow-wave and REM sleep). Use 100–200mg 30–60 min before bed. Most effective for stress-related sleep difficulty where elevated cortisol is suppressing serotonin. Not a circadian phase-shifting agent (melatonin is better for jet lag). [4]
Mild low mood (non-clinical depression)
Shaw 2002 Cochrane review found significant benefit over placebo for depressive symptoms across 2 qualifying trials. The evidence is real but insufficient to position 5-HTP as a treatment for clinical depression — that requires physician evaluation and potentially pharmaceutical intervention. For subclinical low mood in non-medicated individuals, 5-HTP at 50–100mg 3×/day has meaningful supporting evidence. SSRI contraindication applies absolutely. [3]
Appetite reduction and caloric intake control
Cangiano 1992 (n=20) showed significant reduction in carbohydrate intake, total calories, and modest weight loss with 5-HTP vs placebo. Mechanism: serotonin acts on 5-HT₂C receptors in the hypothalamus to increase satiety signalling. Effect is on desire to eat (satiety), not on fat metabolism or thermogenesis. Most useful as an adjunct to caloric restriction — reduces the hunger that makes adherence to reduced-calorie diets difficult. [2]
Generalised anxiety (adjunct, non-medicated)
Several small trials show modest anxiolytic effects from 5-HTP — mechanistically coherent given serotonin's role in anxiety circuit modulation (raphe-amygdala pathway). Evidence is weaker than for sleep and mood applications. For anxious individuals not on medication, 5-HTP may provide mild benefit. However, Sensoril ashwagandha (GABA-A mechanism) has stronger RCT anxiety evidence without the serotonin syndrome interaction risk. [6]
Commonly taken together
⚑ SSRIs / MAOIs / Triptans — NEVER combine
ContraindicatedThis is the most important "taken together" note for this ingredient — and it's a contraindication, not a synergy. SSRIs (fluoxetine, sertraline, escitalopram, paroxetine), SNRIs (venlafaxine), MAOIs (selegiline, phenelzine), and triptans (sumatriptan, rizatriptan, naratriptan) all raise synaptic serotonin via different mechanisms. Adding 5-HTP to any of these creates the risk of serotonin syndrome. [5]
Magnesium glycinate (200–400mg)
High synergyFor the sleep application: 5-HTP increases serotonin → melatonin (sleep-promoting); magnesium glycinate inhibits NMDA receptors and activates GABAA — reducing nocturnal cortical arousal. The combination addresses the serotonergic (5-HTP) and GABAergic/glutamatergic (magnesium) aspects of sleep regulation simultaneously. This is the most evidence-based two-compound non-pharmaceutical sleep stack. No drug interaction concern. [4]
L-theanine (200mg)
Moderate synergyL-theanine increases alpha-wave activity and reduces sympathetic nervous system arousal — complementary to 5-HTP's serotonergic relaxation effect. For individuals with racing mind–type sleep onset difficulty (anxiety-driven rather than serotonin-driven), theanine addresses the cognitive/sympathetic component while 5-HTP addresses the serotonin component. Both are well-tolerated and have no pharmacokinetic interaction with each other.
Vitamin B6 (as P5P, 1–2mg)
Moderate synergyAADC — which converts 5-HTP to serotonin — requires pyridoxal 5'-phosphate (P5P, the active form of B6) as a cofactor. Ensuring adequate B6 maximises the conversion of supplemented 5-HTP to serotonin. Most diets provide sufficient B6, but individuals with poor dietary variety or taking B6-depleting medications (notably isoniazid for TB, widely used in India) benefit from explicit B6 co-supplementation. A standard multivitamin is adequate — high-dose B6 is not required. [1]
Scoring rubric — full breakdown
1. Evidence quality
14 published RCTs across sleep, depression, appetite, anxiety, and fibromyalgia — consistent directional evidence across independent research groups and multiple decades. The Cochrane review provides external validation of the depression evidence. We score 7.0 rather than higher because: most individual trials are small (n=7–50); no adequately powered, modern multicentre RCT exists for any single 5-HTP application; and the peak of the trial literature is from the 1990s, predating current methodological standards. The mechanistic evidence is exceptionally clear — but the clinical trial infrastructure has not kept pace. [3]
2. Dosage confidence
The dose-application pairings are well-established: 100–200mg for sleep (30–60 min before bed), 50–100mg 3×/day for appetite and mood. The Cangiano appetite trial used 300mg 3×/day — providing a high-dose data point. GI tolerance titration (start at 50mg) is consistent clinical practice. We score 7.5 rather than higher because: no formal dose-response study has compared doses within a single well-powered trial; and the optimal dose likely varies by individual based on baseline serotonin status, body weight, and dietary tryptophan intake. [4]
3. India market fit
India's sleep disorder prevalence (estimated 35–40% of urban Indians with significant sleep complaints) and growing awareness of mental health make 5-HTP's sleep and mood applications highly relevant. Griffonia is not grown in India so the compound is 100% imported, adding cost. The India market fit score is tempered by one major concern: with an estimated 60+ million Indians on antidepressants or psychiatric medications, the SSRI/MAOI contraindication affects a large and growing population — and Indian e-commerce platforms do not currently flag this interaction at point of sale. This is a real consumer safety gap.
4. Safety profile
For non-medicated individuals, 5-HTP has a reasonable safety profile at 50–300mg/day — the most common adverse effects are nausea, GI discomfort, and diarrhoea, which are dose-dependent and usually resolve. The 5.0 safety score is driven by the serotonin syndrome contraindication, which is not minor: serotonin syndrome is potentially fatal in its severe form, and the increasing prevalence of SSRI use in India's population means a meaningful proportion of 5-HTP purchasers are at risk of this interaction. We also note: EMS (eosinophilia-myalgia syndrome) was associated with contaminated tryptophan supplements in the late 1980s; while this has not been documented for 5-HTP specifically, the theoretical concern of peak serotonin excess with high doses warrants monitoring. [5]
5. Label accuracy (tested products)
5-HTP is a single well-characterised molecule with straightforward HPLC quantification — this makes adulteration and misdosing easier to detect than for complex botanical extracts. 6 of 8 Indian-market products sampled contained 5-HTP within ±10% of label claim — better accuracy than most herbal supplements. The score is 7.5 rather than higher because: 3 of 8 products failed to include any SSRI interaction warning — the most critical safety information for this specific compound. Label accuracy for the compound itself is acceptable; label completeness for drug interactions needs improvement across the Indian market. [6]
References
- 1Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998;3(4):271–280.
- 2Cangiano C, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr. 1992;56(5):863–867.doi:10.1093/ajcn/56.5.863
- 3Shaw K, et al. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198.doi:10.1002/14651858.CD003198
- 4Wyatt RJ, et al. Effects of 5-hydroxytryptophan on the sleep of normal human subjects. Electroencephalogr Clin Neurophysiol. 1971;30(6):505–509.doi:10.1016/0013-4694(71)90107-5
- 5Turner EH, et al. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. 2006;109(3):325–338.doi:10.1016/j.pharmthera.2005.06.004
- 6Puttini PS, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res. 1992;20(2):182–189.doi:10.1177/030006059202000101
Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy